Stock

Ozempic, Wegovy covered by Medicare and Medicaid under Biden admin proposal for anti-obesity GLP-1 drugs

Published

Under the proposed rule by the Biden administration, anti-obesity drugs such as Ozempic and Wegovy would be covered by Medicare and Medicaid. These are GLP-1 inhibitors, a class of drugs that help control blood sugar levels in individuals with type 2 diabetes. The proposal suggests that these drugs would be covered when used to treat obesity or overweight with at least one weight-related condition. However, this proposal will need to go through the appropriate channels before it becomes official, so please keep an eye on the latest updates regarding this matter. Is there anything else you would like to know?

In this article:

You May Also Like

Editor's Pick

Air travel demand is breaking records. Airline profits are not.

This statement indicates that despite the increase in the number of people choosing to travel by air, which is creating a record-breaking demand, the...

July 8, 2024

Editor's Pick

Family Dollar to close almost 1,000 stores

That’s correct. Dollar Tree, the parent company of the budget stores Family Dollar and Dollar Tree, announced in 2019 that it would close nearly...

March 14, 2024

Economy

The conman, his lovers and the mother who vanished

It sounds like you’re interested in creating a narrative or story around these characters. Let’s set up how they might interact. — Once upon...

March 3, 2024

Editor's Pick

Rite Aid wrongfully used facial recognition to accuse customers of shoplifting, FTC says

The Federal Trade Commission (FTC) recently announced that it has reached a settlement with drugstore chain Rite Aid over its “improper use of facial...

December 24, 2023

Disclaimer: Financeflowinsider.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2024 financeflowinsider.com

Exit mobile version